BioCentury
ARTICLE | Finance

Functions of formulation

How Halozyme is growing its business around licensing reformulation technology

August 4, 2018 12:46 AM UTC

Halozyme Therapeutics Inc. is quickly expanding the reach of its Enhanze platform on the back of regulatory approvals for products that are now gaining market share, plus a playbook for streamlined early development it can provide to partners.

The company has added as many new partners for its subcutaneous formulation platform in the last four years, since the first Enhanze approval, as it did in the prior six. It also has almost quadrupled the value of upfront and milestone payments compared to the total value of deals made before the first Enhanze product was approved...

BCIQ Company Profiles

Halozyme Therapeutics Inc.

BCIQ Target Profiles

Hyaluronan